Global Theranostics Market Size study & Forecast, by Application (Oncology, Neurology, Cardiology, Infectious Diseases), by Technology (Genomics, Proteomics, Metabolomics, Biomarkers), and Regional Forecasts 2025-2035

The Global Theranostics Market, valued at approximately USD 9.17 billion in 2024, is projected to expand at an impressive CAGR of 11.77% between 2025 and 2035. Theranostics, an innovative field that merges diagnostics with targeted therapy, is transforming the landscape of precision medicine by enabling clinicians to both detect and treat diseases using a single, integrated approach. By leveraging advanced molecular imaging, biomarker profiling, and companion diagnostics, theranostics facilitates personalized treatment strategies that significantly improve patient outcomes while reducing unnecessary therapeutic interventions. The rising prevalence of chronic and life-threatening conditions such as cancer, cardiovascular disorders, and neurological diseases is catalyzing demand for these advanced solutions. Increasing investment in genomic and proteomic research, coupled with advances in molecular imaging modalities, is further propelling market growth as healthcare systems pivot toward outcome-based care models.

The surge in adoption of theranostic approaches stems from their ability to shorten diagnostic timelines, optimize treatment regimens, and minimize adverse effects. In oncology, theranostics is proving to be a game changer by pairing diagnostic imaging agents with targeted radiopharmaceuticals to treat tumors more effectively. According to recent clinical trial data, patient survival rates for certain cancers have improved markedly when theranostic solutions were deployed early in the treatment cycle. Furthermore, the integration of AI-powered analytics with biomarker-based screening is enabling healthcare providers to detect disease progression at a molecular level long before symptoms emerge, opening new avenues for preventive medicine. Despite these advancements, the market faces challenges such as high development costs, stringent regulatory frameworks, and limited access to cutting-edge diagnostic infrastructure in low-resource regions.

Regionally, North America is anticipated to maintain its leadership position in the theranostics market in 2025, supported by robust R&D investment, a well-established biopharmaceutical sector, and rapid adoption of precision medicine frameworks. The region’s favorable reimbursement landscape, combined with the presence of leading diagnostic imaging and pharmaceutical companies, further cements its dominance. Europe follows closely, driven by strong government initiatives promoting personalized healthcare, as well as growing academic–industry collaborations in biomarker discovery. The Asia Pacific region is expected to witness the fastest growth over the forecast period, fueled by expanding healthcare infrastructure, surging demand for early disease detection, and an increasing prevalence of lifestyle-related disorders. Nations like China, India, and Japan are investing heavily in advanced molecular diagnostic platforms and clinical research programs to address rising healthcare burdens.

Major market player included in this report are:
• Siemens Healthineers AG
• GE HealthCare Technologies Inc.
• F. Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific Inc.
• Abbott Laboratories
• Philips Healthcare
• Agilent Technologies, Inc.
• Illumina, Inc.
• Danaher Corporation
• Qiagen N.V.
• Bayer AG
• Bracco Imaging S.p.A.
• Cardinal Health, Inc.
• PerkinElmer, Inc.
• Lantheus Holdings, Inc.

Global Theranostics Market Report Scope:
• Historical Data – 2023, 2024
• Base Year for Estimation – 2024
• Forecast period - 2025-2035
• Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within the countries involved in the study. The report also provides detailed information about crucial aspects, such as driving factors and challenges, which will define the future growth of the market. Additionally, it incorporates potential opportunities in micro-markets for stakeholders to invest, along with a detailed analysis of the competitive landscape and product offerings of key players.

The detailed segments and sub-segments of the market are explained below:

By Application:
• Oncology
• Neurology
• Cardiology
• Infectious Diseases

By Technology:
• Genomics
• Proteomics
• Metabolomics
• Biomarkers

By End User:
• Hospitals
• Diagnostic Laboratories
• Research Institutes

By Product Type:
• Instruments
• Reagents
• Software

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE

Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC

Latin America
• Brazil
• Mexico

Middle East & Africa
• UAE
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Key Takeaways:
• Market Estimates & Forecast for 10 years from 2025 to 2035.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions. Show more